Systemic immune challenge exacerbates neurodegeneration in a model of neurological lysosomal disease.
Oriana MandolfoHelen ParkerÈlia AguadoYuko Ishikawa LearmonthAi Yin LiaoClaire O'LearyStuart EllisonGabriella ForteJessica TaylorShaun WoodRachel SearleRebecca J HolleyHervé BoutinBrian W BiggerPublished in: EMBO molecular medicine (2024)
Mucopolysaccharidosis type IIIA (MPS IIIA) is a rare paediatric lysosomal storage disorder, caused by the progressive accumulation of heparan sulphate, resulting in neurocognitive decline and behavioural abnormalities. Anecdotal reports from paediatricians indicate a more severe neurodegeneration in MPS IIIA patients, following infection, suggesting inflammation as a potential driver of neuropathology. To test this hypothesis, we performed acute studies in which WT and MPS IIIA mice were challenged with the TLR3-dependent viral mimetic poly(I:C). The challenge with an acute high poly(I:C) dose exacerbated systemic and brain cytokine expression, especially IL-1β in the hippocampus. This was accompanied by an increase in caspase-1 activity within the brain of MPS IIIA mice with concomitant loss of hippocampal GFAP and NeuN expression. Similar levels of cell damage, together with exacerbation of gliosis, were also observed in MPS IIIA mice following low chronic poly(I:C) dosing. While further investigation is warranted to fully understand the extent of IL-1β involvement in MPS IIIA exacerbated neurodegeneration, our data robustly reinforces our previous findings, indicating IL-1β as a pivotal catalyst for neuropathological processes in MPS IIIA.
Keyphrases
- poor prognosis
- drug induced
- liver failure
- end stage renal disease
- cerebral ischemia
- emergency department
- newly diagnosed
- chronic obstructive pulmonary disease
- toll like receptor
- multiple sclerosis
- intensive care unit
- type diabetes
- chronic kidney disease
- immune response
- inflammatory response
- white matter
- single cell
- cell death
- stem cells
- early onset
- aortic dissection
- machine learning
- risk assessment
- cell therapy
- bipolar disorder
- ionic liquid
- brain injury
- signaling pathway
- peritoneal dialysis
- gold nanoparticles
- human health
- replacement therapy
- nuclear factor
- subarachnoid hemorrhage
- patient reported outcomes
- insulin resistance
- patient reported